Romberger Timothy 4
4 · Cyteir Therapeutics, Inc. · Filed Jun 24, 2021
Insider Transaction Report
Form 4
Romberger Timothy
Director
Transactions
- Conversion
Series B Convertible Preferred Stock
2021-06-22−200,000→ 0 total→ Common Stock (58,670 underlying) - Conversion
Series A Convertible Preferred Stock
2021-06-22−69,503→ 0 total→ Common Stock (20,390 underlying) - Conversion
Common Stock
2021-06-22+79,060→ 369,448 total
Footnotes (1)
- [F1]Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.